Published in Thromb Haemost on October 01, 1999
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
Neonatal coagulation problems. Arch Dis Child Fetal Neonatal Ed (2004) 1.53
Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut (2005) 0.95
National and international registries of rare bleeding disorders. Blood Transfus (2008) 0.86
A neonatal presentation of factor V deficiency: a case report. BMC Pediatr (2007) 0.79
Factor V Deficiency in Korean Patients: Clinical and Laboratory Features, Treatment, and Outcome. J Korean Med Sci (2016) 0.75
Update on inherited disorders of haemostasis and pregnancy. Obstet Med (2016) 0.75
The Role of Frontal-Subcortical Circuitry in Neuropsychological Deficit of Attention: Hypothesis and Results in Two Coagulation Disorders. Front Hum Neurosci (2016) 0.75
Congenital afibrinogenemia: a case report of a spontaneous hepatic hematoma. Medicine (Baltimore) (2016) 0.75
A Rare Case of Inherited Factor-II Deficiency Causing Life-Threatening Menorrhagia. Ann Med Health Sci Res (2012) 0.75
Congenital bleeding disorders and dental surgery. Evid Based Dent (2015) 0.75
Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation. Thromb Haemost (2016) 0.75
[Congenital afibrinogenemia: about a case]. Pan Afr Med J (2016) 0.75
Rare coagulation disorders: an emerging issue. Blood Transfus (2007) 0.75
Rare coagulation disorders: a retrospective analysis of 156 patients in Turkey. Turk J Haematol (2012) 0.75
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol (1993) 1.40
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis (1996) 1.39
Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost (1999) 1.38
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol (1999) 1.38
Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost (1994) 1.38
Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med (1983) 1.38
Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol (1995) 1.37
Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia (2006) 1.36
Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost (1983) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood (1992) 1.31
Deficiencies of protein C, an inhibitor of blood coagulation. Lancet (1982) 1.28
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia (2008) 1.28
Platelet volume and shape in relation to aggregation and adhesion. Br J Haematol (1967) 1.27
Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med (2000) 1.26
Asymptomatic liver disease in haemophiliacs. J Clin Pathol (1975) 1.26
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol (1998) 1.24
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. Blood (1992) 1.22
Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia (2002) 1.21
Binding of fibrinogen to human monocytes. J Clin Invest (1986) 1.20
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol (1992) 1.20
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
Risk of cerebral vein thrombosis and oral contraceptives. Lancet (1998) 1.18
Rare coagulation deficiencies. Haemophilia (2002) 1.18
Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol (1989) 1.18
Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet (1997) 1.17
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost (1997) 1.17
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost (1999) 1.17
Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood (1997) 1.15
Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol (1999) 1.13
Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol (1999) 1.12
Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease. Br J Haematol (1976) 1.12
Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med (1978) 1.12
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost (1985) 1.10
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia (2008) 1.10
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Platelets and the vessel wall: how much aspirin? Lancet (1980) 1.09
Hypercoagulability in centenarians: the paradox of successful aging. Blood (1995) 1.08
Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost (2006) 1.08
Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost (2004) 1.08
Multicenter study of homocysteine measurement--performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost (2001) 1.08
High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology (1996) 1.07
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost (2006) 1.07
Multiple polymorphic sites in factor X locus. Blood (1988) 1.07
Factor VIII and chronic renal failure. Br Med J (1977) 1.06
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost (2007) 1.05
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol (1999) 1.05
Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet (1976) 1.05
Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol (1986) 1.05
ABO blood group and thrombotic vascular disease. Thromb Haemost (2014) 1.05
Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol (2000) 1.04